XOMA acquires IXINITY royalty and milestone payments from Aptevo for $9.6M

XOMA Royalty Corp

XOMA (US) LLC paid $9.6M to Aptevo for 100% of deferred payments on IXINITY net sales, plus partial milestone payments.
IXINITY is a hemophilia B treatment marketed by Medexus; purchased receivables stem from a 2020 Aptevo-Medexus sale agreement.
Additional $50k payment to Aptevo if XOMA receives >$500k of Q1 2023 deferred payments from IXINITY.
Agreement includes customary covenants, representations, and indemnification provisions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

XOMA Royalty Corp entered into Payment Interest Purchase Agreement with Aptevo Therapeutics Inc. valued at $9.6 million (effective 2023-03-29).

Action: entry
Agreement: asset purchase
Counterparty: Aptevo Therapeutics Inc.
Value: $9.6 million
Effective: 2023-03-29

Exact text from the filing

On March 29, 2023, XOMA (US) LLC (“XOMA”), a wholly-owned subsidiary of XOMA Corporation (the “Company”), entered into a Payment Interest Purchase Agreement (the “Agreement”) with Aptevo Therapeutics Inc., a Delaware corporation (“Aptevo”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

XOMA Royalty Corp filing history →

Source: SEC EDGAR

accession 0001193125-23-084515

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.